Review: The Discovery and Development of Sildenafil Citrate

Authors

  • Eza Azhara Septifani School of Pharmaceutical Science (STIFARM), Padang, Indonesia
  • Rina Desni Yetti School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147
  • Ridho Asra School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147

DOI:

https://doi.org/10.22270/ajprd.v9i4.1018

Keywords:

Griseofulvin, Dermatophyte, Toxicity.

Abstract

Background: Griseofulvin is a fungistatic antifungal drug used to treat dermatophytosis. Dermatophytes that are often found include Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum canis, Microsporum gypseum, Epidermophyton floccosum. Purpose: This review article aims to discuss the drug discovery review of griseofulvin. Data Source: The author created this review article using the literature study method relevant to the purpose of the review. Sources of information from national journals and international journals that are accessed through online sites such as Google Scholar, Research Gate, Science Direct, Springer Link, and NCBI. Key words were used to find the journals, namely griseofulvin, dermatophyte, toxicity. Conclusion: The conclusion of this article is that griseofulvin is used as an antifungal drug containing chlorine from Penicillium griseofulvum isolated against mycelium fungus. This drug is non-toxic, so it is effective and safe to fight various types of fungal infections of the skin such as tinea capitis and remains the drug of choice for dermatophytes. 

Downloads

Download data is not yet available.

Author Biographies

Eza Azhara Septifani, School of Pharmaceutical Science (STIFARM), Padang, Indonesia

School of Pharmaceutical Science (STIFARM), Padang, Indonesia

Rina Desni Yetti, School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147

School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147

Ridho Asra, School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147

School of Pharmaceutical Science (STIFARM) Padang, Indonesia 25147

References

1. A. R. Mccullough, “Review Empat Tahun Sildenafil Citrate,” 2002; 4: 26–38.
2. I. Goldstein, T. F. Lue, H. Padma-Nathan, R. C. Rosen, W. Steers, and P. A. Wicker, “Sildenafil in the treatment of erectile dysfunction.,” N. Engl. J. Med., 1998; 339(10):1397–1404, 1998.
3. I. Goldstein, A. L. Burnett, R. C. Rosen, P. W. Park, and V. J. Stecher, “The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction,” Sex. Med. Rev., vol. 7, no. 1, pp. 115–128, 2019, doi: 10.1016/j.sxmr.2018.06.005.
4. Rohmah R, Salawati T, Larasaty ND. 2019. Perilaku Penjual Obat Kuat (Aphrodisiac)di Wilayah Kota Semarang. Prosiding Mahasiswa Seminar Nasional Unimus.2019; l.2:46 - 51.
5. Eriska Boru S. Analisis Kandungan Sildenafil Sitrat Dalam “Pil Biru” Yang Dijual di Daerah Ciputat. 2014: Jakarta. http://repository.uinjkt.ac.id/dspace/bitstream/123456789/25537/1/Eriska%20Boru%20Saragih-%20fkik.
6. Hairunnisa, H. Sulitnya Menemukan Obat Baru di Indonesia. Majalah Farmasetika, 2019; 4(1):16-21.
7. Angga Tiya W.S., “Analisis Sildenafil Sitrat Pada Jamu Tradisional Kuat Lelaki Merk a Dan B Dengan Metode Kromatografi Cair Kinerja Tinggi,” Pharmacy, 2010; 07(02): 24–34.
8. P. J. Dunn, S. Galvin, and K. Hettenbach, “The development of an environmentally benign synthesis of sildenafil citrate (ViagraTM) and its assessment by Green Chemistry metrics,” R. Soc. Chem., 2004; 11(2):223–22, 2004, doi: 10.1039/b815986f.
9. H. W. Hamilton, D. F. Ortwine, D. F. Worth, and J. A. Bristol, “Synthesis and Structure-Activity Relationships of Pyrazolo[4,3-d]pyrimidin-7-ones as Adenosine Receptor Antagonists,” J. Med. Chem.,1987; 30(1):91–96.doi: 10.1021/jm00384a016.
10. N. K. Terrett, A. S. Bell, D. Brown, and P. Ellis, “Sildenafil (Viagra(TM)), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction,” Bioorganic Med. Chem. Lett., 1996; 6(15):1819–1824.doi: 10.1016/0960-894X(96)00323-X.
11. I. H. Osterloh, “The discovery and development of Viagra® (sildenafil citrate),” Sildenafil, 2004; 1–13. doi: 10.1007/978-3-0348-7945-3_1.
12. M. C. Maytom et al., “A two-part pilot study of sildenafil (VIAGRATM) in men with erectile dysfunction caused by spinal cord injury,” Spinal Cord, 1999; l(37):110–116. doi: 10.1038/sj.sc.3100803.
13. J. Y. Jeremy, S. A. Ballard, A. M. Naylor, M. A. W. Miller, and G. D. Angelini, “Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro,” Br. J. Urol., 1997; 79(6):958–963. doi: 10.1046/j.1464-410x.1997.00206.x.
14. G. Wagner, “Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction—by Morales et al,” Int. J. Impot. Res., 1998; 10(2):74 doi: 10.1038/sj.ijir.3900335.
15. J. R. Fishman and L. Mamo, “What’s in a Disorder: A Cultural Analysis of Medical and Pharmaceutical Constructions of Male and Female Sexual Dysfunction,” Women Ther., 2002; 24:179–193. doi: 10.1300/J015v24n01.
16. F. Giuliano, G. Jackson, F. Montorsi, A. Martin-Morales, and P. Raillard, “Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database,” Int. J. Clin. Pract., 2010; 64(2):240–255, doi: 10.1111/j.1742-1241.2009.02254.x.
17. Y.-P. Xie et al., “Sildenafil Prevents and Reverses T-tubule Remodeling and Ca2+ Handling Dysfunction in Right Ventricle Failure Induced by Pulmonary Artery Hypertension,” Hypertension., 2013; 23(1):1–7, doi: 10.1161/HYPERTENSIONAHA.111.180968.Sildenafil.
18. A. R. McCullough, “Four-year review of sildenafil citrate.,” Rev. Urol., 2002; 4(3):S26-38[Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/16986012%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1476025.
19. H. A. Ghofrani, I. H. Osterloh, and F. Grimminger, “Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond,” Nat. Rev. Drug Discov., 2006; 5(8):689–702: doi: 10.1038/nrd2030.
20. D. Abbott et al., “Preclinical safety profile of sildenafil,” Int. J. Impot. Res., 2004; 16(6):498–504. doi: 10.1038/sj.ijir.3901232.
21. S. G. Moreira, R. E. Brannigan, A. Spitz, F. J. Orejuela, L. I. Lipshultz, and E. D. Kim, “Side-effect profile of sildenafil citrate (Viagra) in clinical practice,” Urology, 2000; 56(3):474–476. doi: 10.1016/S0090-4295(00)00649-X.
22. D. R. J. Glenn, N. McClure, S. L. Cosby, M. Stevenson, and S. E. M. Lewis, “Sildenafil citrate (Viagra) impairs fertilization and early embryo development in mice,” Fertil. Steril., 2009; 91(3):893–899.doi: 10.1016/j.fertnstert.2007.12.014.
23. A. Laties and I. Sharlip, “Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction,” J. Sex. Med.,2006; 3(1):12–27.doi: 10.1111/j.1743-6109.2005.00194.x.
24. K. E. Andersson, “PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery,” Br. J. Pharmacol., 2018; 175(13), :2554–2565. doi: 10.1111/bph.14205.
25. M. Zych, A. Roszczyk, M. Kniotek, B. Kaleta, and R. Zagozdzon, “Sildenafil Citrate Influences Production of TNF-α in Healthy Men Lymphocytes,” J. Immunol. Res., 2019, doi: 10.1155/2019/8478750.
26. L. Omarjee, A. Camarzana, S. Henni, and P. Abraham, “Nonrevascularizable buttock claudication improved with Sildenafil A case report,” Med. (United States), 2017; 96(8):8–11 doi: 10.1097/MD.0000000000006186.
27. X. Li et al., “Effect of sildenafil citrate on treatment of infertility in women with a thin endometrium: a systematic review and meta-analysis,” J. Int. Med. Res., 2020; 48(11) doi: 10.1177/0300060520969584.
28. H. Refai, D. Hassan, and R. Abdelmonem, “Development and characterization of polymer-coated liposomes for vaginal delivery of sildenafil citrate,” Drug Deliv., 2017; 24(1): 278–288.doi: 10.1080/10717544.2016.1247925.
29. E. E. Gillis, J. N. Mooney, M. R. Garrett, J. P. Granger, and M. Sasser, “Sildenafil treatment ameliorates the maternal syndrome of preeclampsia and rescues fetal growth in the Dahl Salt Sensitive rat Ellen,” Hypertension., 2017; 67(3):647–653doi: 10.1161/HYPERTENSIONAHA.115.06071.Sildenafil.
30. S. Younis et al., “Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T,” J. Headache Pain, 2018; 19(1) doi: 10.1186/s10194-018-0870-2.
31. H. A. Cakmak, B. Ikitimur, B. Karadag, and Z. Ongen, “An unusual adverse effect of sildenafil citrate: Acute myocardial infarction in a nitrate-free patient,” BMJ Case Rep., 2012; 3–6. doi: 10.1136/bcr-2012-006504.
32. Y. Fatoumata et al., “Sildenafil Citrate Induced Retinal Toxicity - ERG, OCT, and Adaptive Optics findings,” Retin Cases Br. Rep., 2018; 12(1): 1796–803, doi: 10.1097/ICB.0000000000000708.Sildenafil.
33. A. Atipairin, C. Chunhachaichana, T. Nakpheng, N. Changsan, T. Srichana, and S. Sawatdee, “Development of a sildenafil citrate microemulsion-loaded hydrogel as a potential system for drug delivery to the penis and its cellular metabolic mechanism,” Pharmaceutics,2020; 12(11):1–23. doi: 10.3390/pharmaceutics12111055.
34. B. G. A. Stuckey et al., “Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: Results of a randomized controlled trial,” Diabetes Care, 2003; 26(2):279–284. doi: 10.2337/diacare.26.2.279.
35. J. Bloemers et al., “Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: A pharmacokinetic comparison,” Br. J. Clin. Pharmacol., 2016; 81(6):1091–1102. doi: 10.1111/bcp.12887.
36. Y. Lv et al., “Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects,” Clin. Pharmacol. Drug Dev., 2020; 9(5):573–581. doi: 10.1002/cpdd.806.
37. S. Kulshrestha, R. Chawla, M. T. Alam, J. S. Adhikari, and M. Basu, “Efficacy and dermal toxicity analysis of Sildenafil citrate based topical hydrogel formulation against traumatic wounds,” Biomed. Pharmacother., 2019; 112:108571. doi: 10.1016/j.biopha.2019.01.032.
38. L. Di Luigi et al., “Sildenafil reduces expression and release of IL-6 and IL-8 induced by reactive oxygen species in systemic sclerosis fibroblasts,” Int. J. Mol. Sci., 2020; 21(9):1–9, 2020, doi: 10.3390/ijms21093161.
39. N. J. Lubna et al., “Cardiac safety profile of sildenafil: Chronotropic, inotropic and coronary vasodilator effects in the canine isolated, blood-perfused heart preparations,” J. Toxicol. Sci., 2016; 41(6):739–744, 2016, doi: 10.2131/jts.41.739.
40. S. M. Badr-Eldin and O. A. Ahmed, “Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation,” Drug Des. Dev. Ther., 2016; 1323–1333.
41. C. A. Sable and Et.al., ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenfil,” J Am Coll Cardiol, 2017; 70(4):495–503. doi: 10.1016/j.jacc.2017.04.007.2017.
42. S. A. H. Almurumudhe, R. M. Hatem, and H. A. Hussein, “Physiological And Histological Studies Of The Effect Of Sildenafil On Adenine- Induced Nephrotoxicity In The Sprague–Dawley Rat,” Plant Arch., 2021; 21(1):1074–1078, 2021.
43. S. Behiry, A. Rabie, M. Kora, W. Ismail, D. Sabry, and A. Zahran, “Effect of combination sildenafil and gemfibrozil on cisplatin-induced nephrotoxicity; role of heme oxygenase-1,” Ren. Fail., 2018; 40(1):371–378. doi: 10.1080/0886022X.2018.1455596.
44. N. Triadisti and H. Heldawati, “Analisa Kualitatif Sildenafil Sitrat pada Beberapa Produk Jamu Sehat Pria dengan Metode Kromatografi Lapis Tipis di Wilayah Banjarmasin,” J. Curr. Pharm. Scinces,2018; 1(2):42–47.
45. P. Y. Saraswati, H. Kartamihardja, and A. Firmansyah, “ANALISIS SPOT TEST BAHAN KIMIA OBAT SILDENAFIL SITRAT PADA SEDIAAN JAMU,” JSTFI Indones. J. Pharm. Sci. Technol.,2012; 1(2).
46. A. Sae Yoon, S. Sawatdee, C. Woradechakul, K. Sae Chee, and A. Atipairin, “Physicochemical and microbiological stability of the extemporaneous sildenafil citrate oral suspension,” Sci. Pharm., 215; 83(4): 659–670. doi: 10.3797/scipharm.1505-08.
47. S. Sawatdee, C. Pakawatchai, K. Nitichai, T. Srichana, and H. Phetmung, “Why sildenafil and sildenafil citrate monohydrate crystals are not stable?,” Saudi Pharm. J., 2015; 23(5):504–514, 2015, doi: 10.1016/j.jsps.2015.01.019.
48. Mehdi Yonessi dan Madjid Saeedi. A Double-blind Placebo-controlled Evaluation of the Effect of Topical Sildenafilon Erectile Dysfunction. The Journal of Applied Research 2005; 5(2).
49. Akram jamshidzadeh dan negar Azarpira. 2011. The Effects of Topical Sildenafil on Wound Healing in Rat. Iranianjournal of Pharmaceutical Sciences Winter 2011; 7(1) 43-48.
50. F. Damiano et al., “Analysis of illicit dietary supplements sold in the Italian market: Identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS,” Sci. Justice, 2014; 54(3): 228–237. doi: 10.1016/j.scijus.2014.02.009.
51. K. L. Meadows et al., “Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study,” Support. Care Cancer, 2015; 23, 5:1311–1319. doi: 10.1007/s00520-014-2465-z.
52. M. A. Veronin, M. T. Nutan, and U. K. R. Dodla, “Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet,” Ther. Adv. Drug Saf., 214; 5(5):180–189. doi: 10.1177/2042098614543091.
53. K. M. Hosny, N. A. Alhakamy, M. A. Almodhwahi, M. Kurakula, A. M. Almehmady, and S. S. Elgebaly, “Self-nanoemulsifying system loaded with sildenafil citrate and incorporated within oral lyophilized flash tablets: Preparation, optimization, and in vivo evaluation,” Pharmaceutics, 2020; 12(11): 1–22. doi: 10.3390/pharmaceutics12111124.
54. V. T. Bui, C. S. Doan, T. T. V. Tong, and D. C. Le, “Development and Validation of a Simple, Green Infrared Spectroscopic Method for Quantitation of Sildenafil Citrate in Siloflam Tablets of Unknown Manufacturing Formula,” J. Anal. Methods Chem., 2021; 1–10, doi: 10.1155/2021/6616728.
55. H. Patel, M. S. Panchal, and S. Shah, “Formulation and Evaluation of Transdermal Gel of Sildenafil Citrate,” Int. J. Pharm. Res. Allied Sci.,2012; 1(3):103–118, 2012, [Online]. Available: www.ijpras.com.
56. J. Anaissie and W. J. G. Hellstrom, “Clinical use of alprostadil topical cream in patients with erectile dysfunction: A review,” Res. Reports Urol., 2116; 8:123–131. doi: 10.2147/RRU.S68560.
57. K. Gursoy et al., “Effect of sildenafil on wound healing: An experimental study,” Langenbeck’s Arch. Surg., 2010; 395(6):713–718.doi: 10.1007/s00423-009-0471-2.

Published

2021-08-15

How to Cite

Septifani, E. A., Yetti, R. D., & Asra, R. (2021). Review: The Discovery and Development of Sildenafil Citrate. Asian Journal of Pharmaceutical Research and Development, 9(4), 108–117. https://doi.org/10.22270/ajprd.v9i4.1018

Most read articles by the same author(s)

1 2 > >>